C4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Revenue	35.58	20.76	31.1	45.79	33.2	Upgrade
Revenue Growth (YoY)	71.44%	-33.25%	-32.08%	37.93%	55.25%	Upgrade
Cost of Revenue	110.64	117.71	117.84	94.67	78.44	Upgrade
Gross Profit	-75.05	-96.95	-86.75	-48.88	-45.25	Upgrade
Selling, General & Admin	42.12	42.08	42.79	33.25	15.2	Upgrade
Operating Expenses	42.12	42.08	42.79	33.25	15.2	Upgrade
Operating Income	-117.18	-139.03	-129.53	-82.13	-60.45	Upgrade
Interest Expense	-	-1.37	-2.22	-2.15	-1.23	Upgrade
Interest & Investment Income	9.03	6.03	4.29	2.27	0.3	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-	-5.68	Upgrade
EBT Excluding Unusual Items	-108.14	-134.38	-127.46	-82.01	-67.06	Upgrade
Merger & Restructuring Charges	-2.44	-	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	5.4	3.78	-0.71	-1.88	0.1	Upgrade
Other Unusual Items	-	-0.62	-	-	-	Upgrade
Pretax Income	-105.19	-131.21	-128.18	-83.89	-66.96	Upgrade
Income Tax Expense	0.13	1.28	-	-	-0.63	Upgrade
Net Income	-105.32	-132.49	-128.18	-83.89	-66.34	Upgrade
Net Income to Common	-105.32	-132.49	-128.18	-83.89	-66.34	Upgrade
Shares Outstanding (Basic)	69	50	49	46	11	Upgrade
Shares Outstanding (Diluted)	69	50	49	46	11	Upgrade
Shares Change (YoY)	39.75%	1.59%	6.13%	304.93%	728.80%	Upgrade
EPS (Basic)	-1.52	-2.67	-2.62	-1.82	-5.83	Upgrade
EPS (Diluted)	-1.52	-2.67	-2.62	-1.82	-5.83	Upgrade
Free Cash Flow	-65.34	-108.55	-111.44	-88.24	-67.9	Upgrade
Free Cash Flow Per Share	-0.94	-2.19	-2.28	-1.92	-5.97	Upgrade
Gross Margin	-210.92%	-	-278.96%	-106.76%	-136.30%	Upgrade
Operating Margin	-329.30%	-669.83%	-416.56%	-179.39%	-182.10%	Upgrade
Profit Margin	-295.96%	-638.34%	-412.19%	-183.23%	-199.83%	Upgrade
Free Cash Flow Margin	-183.61%	-522.96%	-358.36%	-192.73%	-204.55%	Upgrade
EBITDA	-115.36	-137.15	-127.86	-80.64	-58.83	Upgrade
EBITDA Margin	-	-	-	-176.13%	-177.23%	Upgrade
D&A For EBITDA	1.82	1.88	1.68	1.49	1.62	Upgrade
EBIT	-117.18	-139.03	-129.53	-82.13	-60.45	Upgrade
EBIT Margin	-	-	-	-179.39%	-182.10%	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q